Different effects of growth hormone-releasing hormone (GRH) and somatostatin on growth hormone and stable metabolite of prostaglandin E2, 13,14-dihydro-15-keto-prostaglandin E2 (PGE2-M) in normal subjects

S. Zacharieva, I. Muchá, J. Popova, K. Andonova

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Twenty four healthy subjects were placed in two treatment groups: The first group consisted of twelve subjects in whom growth releasing hormone (GRH) (1 μg/kg · BW) resulted in a marked and sustained elevation of serum growth hormone (GH) and a slight and delayed increase in plasma prostaglandin E2-M. In the second group, consisting also of twelve subjects, somatostatin infusion (500 μg/250 ml) was initiated and maintained for 60 min. Serum GH significantly decreased at 30 and 60 min during infusion and 15 min thereafter. We did not observe any changes in plasma prostaglandin E2-M during or after somatostatin infusion. The results obtained confirm previous in vitro studies and suggest a possible link between growth releasing hormone and prostaglandin E2 in their action on growth hormone secretion. It seems that somatostatin does not play a role in the control of prostaglandin E2 release.

Original languageEnglish
Pages (from-to)209-212
Number of pages4
JournalDiabete et Metabolisme
Volume18
Issue number3
Publication statusPublished - 1992

Fingerprint

Growth Hormone-Releasing Hormone
Somatostatin
Dinoprostone
Growth Hormone
Serum
Healthy Volunteers
11-deoxy-15-keto-13,14-dihydro-11 beta,16-cycloprostaglandin E2
15-ketoprostaglandin E2

Keywords

  • 13, 14-dihydro-15-keto-prostaglandin E
  • GRH
  • healthy subjects
  • somatostatin

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

@article{ee29ba646c664d48ae5c10b8103698fa,
title = "Different effects of growth hormone-releasing hormone (GRH) and somatostatin on growth hormone and stable metabolite of prostaglandin E2, 13,14-dihydro-15-keto-prostaglandin E2 (PGE2-M) in normal subjects",
abstract = "Twenty four healthy subjects were placed in two treatment groups: The first group consisted of twelve subjects in whom growth releasing hormone (GRH) (1 μg/kg · BW) resulted in a marked and sustained elevation of serum growth hormone (GH) and a slight and delayed increase in plasma prostaglandin E2-M. In the second group, consisting also of twelve subjects, somatostatin infusion (500 μg/250 ml) was initiated and maintained for 60 min. Serum GH significantly decreased at 30 and 60 min during infusion and 15 min thereafter. We did not observe any changes in plasma prostaglandin E2-M during or after somatostatin infusion. The results obtained confirm previous in vitro studies and suggest a possible link between growth releasing hormone and prostaglandin E2 in their action on growth hormone secretion. It seems that somatostatin does not play a role in the control of prostaglandin E2 release.",
keywords = "13, 14-dihydro-15-keto-prostaglandin E, GRH, healthy subjects, somatostatin",
author = "S. Zacharieva and I. Much{\'a} and J. Popova and K. Andonova",
year = "1992",
language = "English",
volume = "18",
pages = "209--212",
journal = "Diabetes and Metabolism",
issn = "1262-3636",
publisher = "Elsevier Masson",
number = "3",

}

TY - JOUR

T1 - Different effects of growth hormone-releasing hormone (GRH) and somatostatin on growth hormone and stable metabolite of prostaglandin E2, 13,14-dihydro-15-keto-prostaglandin E2 (PGE2-M) in normal subjects

AU - Zacharieva, S.

AU - Muchá, I.

AU - Popova, J.

AU - Andonova, K.

PY - 1992

Y1 - 1992

N2 - Twenty four healthy subjects were placed in two treatment groups: The first group consisted of twelve subjects in whom growth releasing hormone (GRH) (1 μg/kg · BW) resulted in a marked and sustained elevation of serum growth hormone (GH) and a slight and delayed increase in plasma prostaglandin E2-M. In the second group, consisting also of twelve subjects, somatostatin infusion (500 μg/250 ml) was initiated and maintained for 60 min. Serum GH significantly decreased at 30 and 60 min during infusion and 15 min thereafter. We did not observe any changes in plasma prostaglandin E2-M during or after somatostatin infusion. The results obtained confirm previous in vitro studies and suggest a possible link between growth releasing hormone and prostaglandin E2 in their action on growth hormone secretion. It seems that somatostatin does not play a role in the control of prostaglandin E2 release.

AB - Twenty four healthy subjects were placed in two treatment groups: The first group consisted of twelve subjects in whom growth releasing hormone (GRH) (1 μg/kg · BW) resulted in a marked and sustained elevation of serum growth hormone (GH) and a slight and delayed increase in plasma prostaglandin E2-M. In the second group, consisting also of twelve subjects, somatostatin infusion (500 μg/250 ml) was initiated and maintained for 60 min. Serum GH significantly decreased at 30 and 60 min during infusion and 15 min thereafter. We did not observe any changes in plasma prostaglandin E2-M during or after somatostatin infusion. The results obtained confirm previous in vitro studies and suggest a possible link between growth releasing hormone and prostaglandin E2 in their action on growth hormone secretion. It seems that somatostatin does not play a role in the control of prostaglandin E2 release.

KW - 13, 14-dihydro-15-keto-prostaglandin E

KW - GRH

KW - healthy subjects

KW - somatostatin

UR - http://www.scopus.com/inward/record.url?scp=0026768153&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026768153&partnerID=8YFLogxK

M3 - Article

C2 - 1356837

AN - SCOPUS:0026768153

VL - 18

SP - 209

EP - 212

JO - Diabetes and Metabolism

JF - Diabetes and Metabolism

SN - 1262-3636

IS - 3

ER -